869371-40-4

Basic information

• Product Name: N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide
• Synonyms: N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide
• CAS NO: 869371-40-4
• Molecular Formula: C₉H₁₄N₂O₂S
• Molecular Weight: 214
• Mol File: 869371-40-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide(869371-40-4)
• EPA Substance Registry System: N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide(869371-40-4)

Safety Data

• Hazardous Substances Data: 869371-40-4(Hazardous Substances Data)

Usage

General Description

N-[2-(aminomethyl)phenyl]-N-methylmethanesulfonamide, also known as AG3-5, is a small molecule chemical compound that has been studied for its potential as a therapeutic agent. It is a sulfonamide derivative containing an amine and methyl group, with the potential to act as an anti-inflammatory and neuroprotective agent. The compound has been investigated for its potential use in the treatment of central nervous system disorders, such as epilepsy and Alzheimer's disease. AG3-5 has shown promising results in preclinical studies, demonstrating its ability to reduce inflammation and protect against neuronal damage. Further research is ongoing to explore its therapeutic potential and potential application in clinical settings.

Upstream product

• 394-47-8 2-fluorobenzonitrile 
• 1073159-70-2 N-(2-cyanophenyl)-N-methylmethanesulfonamide 

Downstream Products

• 1372263-39-2 N-(2-(((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)methyl)phenyl)-N-methylmethanesulfonamide 
• 1372262-46-8 N-(2-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)phenyl)-N-methylmethanesulfonamide 
• 1372262-47-9 ethyl 4-(4-(2-(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzoate 
• 1372262-48-0 4-(4-(2(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzoic acid 
• 1372262-49-1 4-(4-(2-(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(3-morpholinopropyl)benzamide 
• 1372262-45-7 4-{[4-({2-[methyl(methylsulfonyl)amino]benzyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-N-(3-morpholin-4-ylpropyl)benzamide 
• 1372263-36-9 N-(2-(((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino)methyl)phenyl)-N-methylmethanesulfonamide 
• 7114-24-1 N-(2-acetylphenyl)-N-methylmethanesulfonamide 
• 1257706-98-1 racemic N-[2-(1-aminoethyl)phenyl]-N-methylmethanesulfonamide 
• 1227487-90-2 N-(2-(aminomethyl)phenyl)-N-methylmethanesulfonamide hydrochloride 
• 1095647-90-7 C₂₂H₂₁F₃N₆O₃S 
• 1095648-01-3 C₂₁H₂₁F₃N₆O₄S₂ 
• 1095647-95-2 C₂₁H₂₂F₃N₅O₄S₂ 
• 717906-29-1 PF-431396 

Relevant articles and documents

Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study

Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase responsible for development of various tumor types. Aiming to explore new potent inhibitors, two series of 2,4-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives were designed and synthesized on the base of structure-based design strategy. Biological evaluation indicated that most of these new compounds could potently inhibit FAK kinase, leading to the promising inhibitors against the proliferation of U-87MG, A-549, and MDA-MB-231 cancer cell lines. Among them, the optimized compound 18h potently inhibited the enzyme (IC50 = 19.1 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.35, 0.24, and 0.34 μM, respectively. Compound 18h is a multi-target kinase inhibitor. Furthermore, compound 18h also exhibited relatively less cytotoxicity (IC50 = 3.72 μM) toward a normal human cell line, HK2. According to the flow cytometry and wound healing assay results, compound 18h effectively induced apoptosis and G0/G1 phase arrest of MDA-MB-231 cells and suppressed the migration of U-87MG, A-549 and MDA-MB-231 cells. The docking study of compound 18h was performed to elucidate its possible binding modes and to provide a structural basis for the further structural guidance design of FAK inhibitors. Collectively, these data support the further development of compound 18h as a lead compound for FAK-targeted anticancer drug discovery.

PYRROLOPYRIMIDINES AS FAK AND ALK INHIBITERS FOR TREATMENT OF CANCERS AND OTHER DISEASES

Disclosed are compounds which inhibit the activity of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), compositions containing the compounds, and methods of treating diseases during which FAK and ALK are expressed. The diseases are, for example, cancers.

PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.